Drug Trial Radar · NCT02896101
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
755
Actual
Start
Aug 2016
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. IndiaIndustry
- Sponsor type
- Industry
- First posted
- Sep 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%Drug
Elidel® (pimecrolimus) CreamDrug
Placebo of Pimecrolimus Cream, 1%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects in each treatment group with treatment success (i.e., a grade of clear or almost clear; a score of 0 or 1, within the treatment area) based on the IGA of Disease Severity at the end of treatment (Visit 3; Day 15 ± 3).Time frame: Day 15
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site 4
Hot Springs, Arkansas
Investigational Site 22
Little Rock, Arkansas
Investigational Site 20
Anaheim, California
Investigational Site 13
Fremont, California
Investigational Site 26
Norco, California
Investigational Site 17
Doral, Florida
Investigational Site 9
Hialeah, Florida
Investigational Site 16
Miami, Florida
Investigational Site 18
Miami, Florida
Investigational Site 19
Miami, Florida
Investigational Site 25
Miami, Florida
Investigational Site 8
Miami, Florida
Investigational Site 12
North Miami Beach, Florida
Investigational Site 3
Ormond Beach, Florida
Investigational Site 7
South Miami, Florida
Investigational Site 10
Tampa, Florida
Investigational Site 24
Tampa, Florida
Investigational Site 14
West Palm Beach, Florida
Investigational Site 1
Arlington Heights, Illinois
Investigational Site 21
Lake Charles, Louisiana
Investigational Site 2
Silver Spring, Maryland
Investigational Site 11
Saint Joseph, Missouri
Investigational Site 27
East Windsor, New Jersey
Investigational Site 5
High Point, North Carolina
Investigational Site 23
Raleigh, North Carolina
Investigational Site 15
Cincinnati, Ohio
Investigational Site 6
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.